GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq: GNVC) announced today that it has signed a Cooperative Research and Development Agreement (“CRADA”) with the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (NIH), to develop adenovector-based vaccines for the prevention and treatment of respiratory syncytial virus (“RSV”). The collaborative research will combine NIAID’s scientific and clinical expertise in RSV with GenVec’s expertise in development of adenovector-based vaccines and proprietary manufacturing process. In addition to the RSV collaboration, GenVec is working with the NIAID on the clinical development of HIV and influenza vaccines.
